about
Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.Newer anticonvulsants: comparative review of drug interactions and adverse effects.Reduced ceramide synthase 2 activity causes progressive myoclonic epilepsyEffect of antiepileptic drugs on cognitive function in individuals with epilepsy: a comparative review of newer versus older agents.A prospective observational longitudinal study of new-onset seizures and newly diagnosed epilepsy in dogs.Quantitative Electroencephalography as a Diagnostic Tool for Alzheimer's Dementia in Adults with Down Syndrome.Pharmacokinetic interactions between contraceptives and antiepileptic drugs.Managing antiepileptic drugs during pregnancy and lactation.Epilepsy and risk of death and sudden unexpected death in the young: a nationwide study.Interactions between hormonal contraception and antiepileptic drugs: Clinical and mechanistic considerations.Management of antiepileptic treatment after epilepsy surgery - practices and problems.Welfare consequences for people with epilepsy and their partners: A matched nationwide study in Denmark.Socioeconomic outcome of epilepsy surgery: A controlled national study.Socioeconomic evaluation of vagus stimulation: A controlled national study.Promising effect of vagal stimulation in Danish patients with epilepsy.Pharmacokinetics of antiepileptic drugs in pregnancy.A single-blinded phenobarbital-controlled trial of levetiracetam as mono-therapy in dogs with newly diagnosed epilepsy.Drug treatment of epilepsy in the 1990s. Achievements and new developments.Aberrant expression of miR-218 and miR-204 in human mesial temporal lobe epilepsy and hippocampal sclerosis-convergence on axonal guidance.Treatment of pediatric epilepsies with gamma-vinyl GABA (vigabatrin).Lamotrigine plasma levels reduced by oral contraceptives.[Preoperative and postoperative magnetoencephalography in a patient with partial epilepsy]Oral contraceptives reduce lamotrigine plasma levels.Epilepsy and pregnancy: lamotrigine as main drug used.A prospective, randomized, multicentre trial for the treatment of refractory status epilepticus; experiences from evaluating the effect of the novel drug candidate, NS1209.Seizure frequency in pregnant women treated with lamotrigine monotherapy.Influences on seizure activity in pregnant women with epilepsy.Seizure deterioration in women treated with oxcarbazepine during pregnancy.[Valproate treatment during pregnancy: description of four cases with foetal valproate syndrome].Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry.Individual changes in lamotrigine plasma concentrations during pregnancy.An oxcarbazepine-related fatality with an overview of 26 oxcarbazepine postmortem cases.Added diagnostic value of magnetoencephalography (MEG) in patients suspected for epilepsy, where previous, extensive EEG workup was unrevealing.Does vagus nerve stimulation influence pregnancy outcomes?Source analysis of epileptic discharges using multiple signal classification analysis.Visualizing spikes in source-space: Rapid and efficient evaluation of magnetoencephalography.No loss in total neuron number in the thalamic reticular nucleus and neocortex in the genetic absence epilepsy rats from Strasbourg.UGT polymorphisms and lamotrigine clearance during pregnancy.[Danish clinical guidelines for epilepsy].[Treatment of epilepsy--where are we now? Danish Society of Epilepsy].
P50
Q33926194-5E42E800-4604-44F4-AA92-F94A1C684A63Q33993665-01337E4C-E0A4-45EF-8769-4E69FC1192ABQ34418788-B12D7651-3F24-41C5-9FD6-47524CA57835Q34563059-9EF5EC99-90D3-4828-9342-61023A176127Q36283408-9D9F9048-B999-4FC1-A7F2-AB554537D067Q36325825-0B1EB608-4041-483B-94A5-95B504C8FDF4Q37060739-C071241E-3558-4C8D-B2AD-D6F29849DECDQ37521649-4E656B9A-DBB8-42A1-B685-9B98CFE438DEQ38124950-9677096B-B446-48A6-8EFA-1634AA78A452Q38406555-85FDC0CE-09A4-4FF5-9341-AEF348898B40Q38612934-803E54BA-F4B0-4502-BBE4-D244896DD7EEQ38770825-9F31AA7F-4E91-4108-9B5D-A1B6E1CB9EA3Q39259199-767082E8-48EF-4255-A036-16AF602A401DQ39334130-30CFBF6F-1AB4-431D-B46A-6D141403468FQ39452749-B31FF4E3-3082-4E3E-8899-B5A75F1354D1Q40138489-2347BB9B-A29E-4550-9325-70711CBE65B1Q41071571-2AE19B1B-A932-4290-AE9F-1EE277194EF3Q41188326-9145C653-7B4D-4751-A1F2-98BA088AD14EQ42775825-EB3AA3A5-DEBC-4A7F-BED2-1002C8CD6091Q43764121-489BB81B-8379-4C60-8C0A-7BE8479571A1Q43774655-F4356A00-DEC0-479B-8767-E0FE3296F58AQ43975734-42ABE23C-DB5D-47BE-B5CA-0F0AF0D555CCQ44562274-1DECF324-6AA2-4CF7-B823-58AD29A12CE4Q44678739-4C7A767B-B52F-4C79-B5D0-8A0657684829Q45413122-F9C7019E-143E-457F-807F-4B6CAB9BB447Q45986019-6A6E4CB8-504C-46DF-94E3-1BDEF5CD572DQ46070797-EE3438F2-4F10-4E2A-B721-44A54CB095DDQ46115452-7CEDF7C2-2A96-4354-B1F9-E7D0866570BFQ46143937-55D10B3E-6F33-42E6-94C4-86CB4B23AE8BQ46319526-4D87A6F2-9DBB-48E1-B87E-30D775AE645FQ46638387-0B2D88D3-4C0A-40EE-9409-CE2DF9BC0CF9Q46883554-7382F7FD-7542-4B1D-A884-FC9557F396F7Q47820834-42B0AA54-6132-4E46-9452-DF8CA409BFE6Q47862837-25191728-B4F6-4C9F-BEE9-2CA61DA33A73Q48429725-568A02E0-60EB-439C-8633-4E8E47200044Q48762605-7A7E5A08-6410-4558-8E7D-137A5F00E8CAQ48847003-C5DC6709-95F8-4310-83F3-D38BCBE8D591Q50208665-B8F41DF1-8978-4783-ADC9-07B712E7DE56Q50543159-33155246-9DB5-4640-A494-9B8F45DD291CQ50579865-46C1A377-6540-4723-BEA3-11A3A7234FE5
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
A Sabers
@ast
A Sabers
@en
A Sabers
@es
A Sabers
@nl
A Sabers
@sl
type
label
A Sabers
@ast
A Sabers
@en
A Sabers
@es
A Sabers
@nl
A Sabers
@sl
prefLabel
A Sabers
@ast
A Sabers
@en
A Sabers
@es
A Sabers
@nl
A Sabers
@sl
P106
P31
P496
0000-0001-8925-213X